Zobrazeno 1 - 10 of 53 pro vyhledávání: '"Concepción, Boqué"'
2
Akademický článek
Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients
Autor: Natalia Estrada, Blanca Xicoy, Fabian Beier, Olga Garcia, Cristian Morales, Concepción Boqué, Miguel Sagüés, Mónica S. Ventura Ferreira, Rolando Vallansot, Sílvia Marcé, Marta Cabezón, Tim H. Brümmendorf, Lurdes Zamora
Publikováno v: HemaSphere, Vol 5, Iss 12, p e657 (2021)
Tyrosine kinase inhibitors have dramatically changed the outcome of chronic myeloid leukemia (CML), and nowadays, one of the main treatment goals is the achievement of deep molecular responses (DMRs), which can eventually lead to therapy discontinuat
Externí odkaz: https://doaj.org/article/eed0d7528f1d408cb71f85ec9f094861
Zobrazit plný text záznamu
3
Association between Germline Single-Nucleotide Variants in ADME Genes and Major Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients
Autor: Natalia Estrada, Lurdes Zamora, Francisca Ferrer-Marín, Laura Palomo, Olga García, Patricia Vélez, Iris De la Fuente, Miguel Sagüés, Marta Cabezón, Montserrat Cortés, Rolando Omar Vallansot, María Alicia Senín-Magán, Concepción Boqué, Blanca Xicoy
Publikováno v: Scientia
Journal of Clinical Medicine; Volume 11; Issue 20; Pages: 6217
Chronic myeloid leukemia; Imatinib; Single-nucleotide polymorphisms Leucèmia mieloide crònica; Imatinib; Polimorfismes d'un sol nucleòtid Leucemia mieloide crónica; Imatinib; Polimorfismos de un sólo nucleótido Imatinib is the most common first
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4df9b0a89f39aecaece2124d53b508dd
http://hdl.handle.net/11351/8974
Zobrazit plný text záznamu
5
Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients
Autor: Marta Cabezón, Cristian Morales, Mónica S. Ventura Ferreira, Natalia Estrada, Rolando Vallansot, Silvia Marcé, Lurdes Zamora, Miguel Sagüés, Concepción Boqué, Fabian Beier, Tim H. Brümmendorf, Olga García, Blanca Xicoy
Publikováno v: Scientia
HemaSphere, Vol 5, Iss 12, p e657 (2021)
HemaSphere
Dipòsit Digital de la UB
Universidad de Barcelona
HemaSphere : open access journal of the European Hematology Association 5(12), e657 (2021). doi:10.1097/HS9.0000000000000657
HemaSphere : open access journal of the European Hematology Association 5(12), e657 (2021). doi:10.1097/HS9.0000000000000657
Published by Wolters Kluwer Health, [Philadelphia, Pennsylvania]
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad32d4a5885bbdc35be5bbc349b82e77
https://hdl.handle.net/11351/9225
Zobrazit plný text záznamu
7
A real-life overview of a hematopoietic cell transplant program throughout a four-year period, including prospective registry, exclusion causes and final donor selection
Autor: Clara Maluquer, M Isabel González-Medina, S Ortega, Cristina Baca, G Bustamante, Rocío Parody, Eva Domingo-Domenech, E Cabezudo, Enric Carreras, V Clapés, Mar Sánchez-Salmerón, Concepción Boqué, A C Oliveira, S. Verdesoto, H Pomares, Montserrat Arnan, Beatriz Patiño, Marta Peña, Santiago Mercadal, Alberto Mussetti, I Sánchez-Ortega, L Escoda, Nadia García, Carme Talarn, C Fusté, Anna Sureda, Juliana Villa, Itziar Carro, Eva González-Barca
Publikováno v: Bone Marrow Transplantation
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Traceability of patients who are candidates for Hematopoietic cell transplant (HCT) is crucial to ensure HCT program quality. Continuous knowledge of both a detailed registry from a HCT program and final exclusion causes can contribute to promoting a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e12f456c2d615b748157d46a8a09b518
https://pubmed.ncbi.nlm.nih.gov/34711917
Zobrazit plný text záznamu
8
The direct and indirect effects of COVID‐19 pandemic in a real‐life hematological setting
Autor: Gabriela Isabel Sanz-Linares, Cristina Baca Cano, Rocío Parody, Helena Pomares, Montserrat Arnan, Adaia Albasanz-Puig, Maria Queralt Salas, Carlota Gudiol, Clara Maluquer, Ana Carla Oliveira Ramos, Anna Sureda, Gabriel Moreno-González, Marta Peña, Alberto Mussetti, Eva Domingo-Domenech, Itziar Carro, Victoria Clapés, Santiago Mercadal, Eva González-Barca, Concepción Boqué, Maria Condom
Publikováno v: Dipòsit Digital de la UB
Universidad de Barcelona
Cancer Reports
Cancer Reports, Vol 4, Iss 4, Pp n/a-n/a (2021)
Background Clinical outcomes of novel coronavirus 2019 disease (COVID‐19) in onco‐hematological patients are unknown. When compared to non‐immunocompromised patients, onco‐hematological patients seem to have higher mortality rates. Aims We de
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a484a6fa22758a0280db4f1a2e34db77
https://doi.org/10.1002/cnr2.1358
Zobrazit plný text záznamu
9
miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk
Autor: Beatriz Bellosillo, E. Luño, Cristina Martínez, Carlos Besses, J.M. Hernández-Rivas, Valentín García-Gutiérrez, Juan Carlos Hernández-Boluda, Natalia Estrada, Patricia Velez, Ernesto J Cuenca, Francisca Ferrer-Marín, Rosa Ayala, C García Hernandez, Vicente Vicente, Concepción Fernández-Rodríguez, D V Fiallo-Suárez, Rosa Cifuentes, Lurdes Zamora, R. Gonzalez-Conejero, A.M. De Los Reyes-Garcia, M. T. Gomez-Casares, Ana Kerguelen, Concepción Boqué, Ana B. Arroyo, Raúl Teruel-Montoya, Beatriz Arrizabalaga, Isabel Arcas, Alberto Alvarez-Larrán
Publikováno v: Digital.CSIC. Repositorio Institucional del CSIC
instname
Leukemia
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Myelofibrosis (MF) occurs as part of the natural history of polycythemia vera (PV) and essential thrombocythemia (ET), and remarkably shortens survival. Although JAK2V617F and CALR allele burden are the main transformation risk factors, inflammation
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a6250465ffa90640689364e4c074012
http://hdl.handle.net/10261/230890
Zobrazit plný text záznamu
10
Asciminib in Real-Life Clinical Practice, Safety and Efficacy Profile in Chronic Myeloid Leukemia Pretreated Patients
Autor: Angeles Escola, Fermín Sánchez-Guijo, Elena Rámila, Elvira Mora Casterá, Juan Carlos Hernandez Boluda, Alejandro Luna, Concepción Boqué, Rocio Fé Bitaube, Valle Gomez, Sunil Lakhwani, Ana García-Noblejas, Melania Moreno Vega, Sara Suarez-Varela, Miguel Sagüés, Valentín García Gutiérrez, Ana Rosell, Luis Serrano, Montse Cortés, Raul Perez Lopez, Juan Luis Steegmann, Ferran Vall-Llovera, Patricia Velez, Antonio Jiménez-Velasco, Carlos Cerveró, Maria Jose Fernández, Mercedes Colorado Araujo, Manuel Mateo Pérez Encinas, Concepción Ruiz Nuño, Antonio Paz Coll, Pilar Giraldo, Natalia de las Heras, Luis Felipe Casado, Araceli Salamanca Cuenca, Lucia Villalon, Beatriz Cuevas, Juan-Manuel Alonso-Domínguez, Carmen Garcia-Hernandez, Lucía Pérez-Lamas, Juan Antonio Juan Vera Goñi, Blanca Xicoy, Patricia Carrascosa Mastell, Alberto Alvarez-Larrán
Publikováno v: Blood. 138:2563-2563
Introduction: asciminib is a first-in-class STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor that potently inhibits aberrant kinase activity of the BCR-ABL1 oncoprotein via allosteric binding. asciminib has shown high efficacy profil
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::66bee1796b3c5134d849ca31522900f6
https://doi.org/10.1182/blood-2021-150813
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje